SAN DIEGO, Oct. 27, 2016 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable information to physicians to improve cancer treatment, announces the appointment of David Moskowitz to the newly created position of Vice President, Strategy and Corporate Communications. Mr. Moskowitz will play a key role in the execution of Biocept's corporate strategy and will coordinate the Company's investor relations and public relations activities.
"Liquid biopsy is emerging as a cornerstone of personalized cancer treatment, and I believe Biocept is positioned to be the commercial leader in this important market segment," said Mr. Moskowitz, 'I'm excited to join the management team and to facilitate Biocept's ability to help cancer patients achieve meaningfully better outcomes, and to create a valuable company for our shareholders."
"We are committed to building on our leadership position in the emerging liquid biopsy field and bringing value to our shareholders," said Michael Nall, President and Chief Executive Officer of Biocept. "David's direct sector experience and 16 years at leading Wall Street firms make him ideally suited to support these corporate goals. David will play an instrumental role in formulating and implementing strategies aimed at our success and will use his proven skills to effectively communicate our progress. We welcome David to the Biocept team."
Most recently, Mr. Moskowitz was Vice President, Investor Relations at Trovagene, a publicly traded molecular diagnostics company. He previously was on Wall Street and served as Director of Equity Research at Caris & Co. and as Head of Healthcare Research at Friedman Billings Ramsey. During his tenure in the financial services industry, Mr. Moskowitz also held analyst positions at UBS Warburg and Roth Capital Partners. In 2011, he received the StarMine Analyst Award as the top stock picker among U.S. Biotechnology Analysts. Mr. Moskowitz has also performed strategic advisory work and capital markets planning for several emerging biopharmaceutical and molecular diagnostics companies. He earned his BS in Pharmacy from Rutgers University and his MBA in Finance and Pharmaceutical Industry Studies at Fairleigh Dickinson University.
Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The Company uses its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer. The Company's patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and in plasma (ctDNA). With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient's disease and therapeutic options. For additional information, please visit www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to our ability to become the commercial leader in the liquid biopsy market, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our Securities and Exchange Commission (SEC) filings. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the SEC, which can be accessed over the Internet at the SEC's website located at www.sec.gov.